ID   FTC-236
AC   CVCL_2446
SY   FTC236
DR   BTO; BTO_0003875
DR   cancercelllines; CVCL_2446
DR   Cell_Model_Passport; SIDM00229
DR   Cosmic; 1239977
DR   ECACC; 06030202
DR   Wikidata; Q54835218
RX   PubMed=1384245;
RX   PubMed=29066502;
RX   PubMed=30737244;
RX   PubMed=31443247;
CC   Population: Caucasian.
CC   Characteristics: Has a near-homozygous genome (NHG) (PubMed=29066502).
CC   Sequence variation: Mutation; HGNC; HGNC:7329; MSH6; Simple; p.Lys1045fs (c.3135delG); Zygosity=Homozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Arg130Ter (c.388C>T); ClinVar=VCV000007819; Zygosity=Homozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:9884; RB1; Simple; p.Arg320Ter (c.958C>T); ClinVar=VCV000126824; Zygosity=Homozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Homozygous; Note=In promoter (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=30737244).
CC   Omics: Genomics; Mitochondrial genome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Misspelling: CFT-236; PubMed=1384245; Note=In the French and Spanish abstracts where the abbreviation 'FTC' was translated to 'CFT' and thus also the cell line names.
CC   Derived from site: Metastatic; Cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): ECACC=06030202; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 11,12
ST   D21S11: 32.2
ST   D3S1358: 15,16
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   D8S1179: 10
ST   FGA: 21
ST   TH01: 9.3
ST   TPOX: 9
ST   vWA: 15,18
DI   NCIt; C8054; Thyroid gland follicular carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1219 ! FTC-133
OI   CVCL_2447 ! FTC-238
SX   Male
AG   42Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 22
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa, Inigo
RA   Pozdeyev, Nikita
RA   Korch, Christopher T.
RA   Marlow, Laura A.
RA   Smallridge, Robert Christian
RA   Copland, John Alton 3rd
RA   Henderson, Ying C.
RA   Lai, Stephen Y.
RA   Clayman, Gary L.
RA   Onoda, Naoyoshi
RA   Tan, Aik-Choon
RA   Garcia-Rendueles, Maria E.R.
RA   Knauf, Jeffrey A.
RA   Haugen, Bryan R.
RA   Fagin, James Alexander
RA   Schweppe, Rebecca E.
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//
RX   PubMed=31443247; DOI=10.3390/cancers11081185; PMCID=PMC6721552;
RA   Aydemirli, Mehtap Derya
RA   Corver, Willem E.
RA   Beuk, Ruben
RA   Roepman, Paul
RA   Solleveld-Westerink, Nienke
RA   van Wezel, Tom
RA   Kapiteijn, Ellen H.W.
RA   Morreau, Hans
RT   "Targeted treatment options of recurrent radioactive iodine refractory
RT   Hurthle cell cancer.";
RL   Cancers (Basel) 11:1185.1-1185.16(2019).
//
RX   PubMed=1384245; DOI=10.1007/BF02067383;
RA   Demeure, Michael Joseph
RA   Damsky, Caroline H.
RA   Elfman, Fred
RA   Goretzki, Peter E.
RA   Wong, Mariwil G.
RA   Clark, Orlo Herrick
RT   "Invasion by cultured human follicular thyroid cancer correlates with
RT   increased beta 1 integrins and production of proteases.";
RL   World J. Surg. 16:770-776(1992).
//
RX   PubMed=29066502; DOI=10.1530/ERC-17-0288;
RA   Corver, Willem E.
RA   Demmers, Joris
RA   Oosting, Jan
RA   Sahraeian, Shima
RA   Boot, Arnoud
RA   Ruano, Dina
RA   van Wezel, Tom
RA   Morreau, Hans
RT   "ROS-induced near-homozygous genomes in thyroid cancer.";
RL   Endocr. Relat. Cancer 25:83-97(2018).
//